In this section we highlight drugs that recently received approval for migraine treatment (TPM) or are available and sometimes used off-label. All drugs discussed in this section are for the ...

Migraine is a common neurological syndrome that affects approximately 10–20% of the population. The pathophysiology of migraine is unclear. 5-hydroxytriptamine is a key mediator in the ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

If you’re a longtime migraine warrior, you’re probably well aware of amitriptyline, and might even consider it an old friend (or foe?) in your migraine toolbox. But if you’re new to the ...

In children and teenagers, treatment with zonisamide was associated with a significant reduction in the number of monthly ...

European approval is based on two pivotal phase 3 clinical trials that enrolled patients with disabling migraine and studied Ajovy as a prophylactic treatment for migraine in adults.

Significant reduction seen in median headache days per month in both intractable and nonintractable migraine groups. HealthDay News — For pediatric patients with migraine, prophylactic ...

Migraine is a frequent and disabling episodic headache with autonomic disturbances. Migraine attacks are usually treated with antiemetics followed by either analgesics or specific migraine drugs ...

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment.

A Migraine attack is described as a debilitating episode of headache characterised by intense throbbing or pulsating pain, usually on one side of the head which is often accompanied by symptoms ...